生基医药 Wx Atu

As the leading specialized Contract Development and Manufacturing Organization (CDMO),WX ATU focused on the cell and gene therapy sector. Our facility operates under an internationally recognized cGMP-compliant quality system, having successfully passed on-site inspections by Chinese regulatory authorities, as well as EU QP audits. Meanwhile, the FDA on-site inspection has already been completed in the first half of 2025. With robust, end-to-end process development capabilities, WX ATU is committed to providing global clients with efficient, compliant, and scalable CDMO services, covering the entire journey from sequence to drug product to accelerate the clinical and commercial advancement of innovative therapies. Leveraging the solid technical and quality foundation, WX ATU has built an integrated CDMO platform encompassing plasmid production, viral vector manufacturing, cell therapy, and regulatory submission services.